• Je něco špatně v tomto záznamu ?

Utilizing neurodegenerative markers for the diagnostic evaluation of amyotrophic lateral sclerosis

K. Klíčová, J. Mareš, K. Menšíková, M. Kaiserová, D. Friedecký, P. Kaňovský, M. Strnad, R. Matěj

. 2024 ; 29 (1) : 31. [pub] 20240106

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24007639

Grantová podpora
CZ.02.1.01 / 0.0 / 0.0 / 16_019 / 0000868 European Regional Development Fund - ENOCH project
NV19-04-00090 Grant Agency of the Ministry of Health

BACKGROUND: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterized by progressive deterioration of upper and lower motor neurons. A definitive diagnostic test or biomarker for ALS is currently unavailable, leading to a diagnostic delay following the onset of initial symptoms. Our study focused on cerebrospinal fluid (CSF) concentrations of clusterin, tau protein, phosphorylated tau protein, and beta-amyloid1-42 in ALS patients and a control group. METHODS: Our study involved 54 ALS patients and 58 control subjects. Among the ALS patients, 14 presented with bulbar-onset ALS, and 40 with limb-onset ALS. We quantified biomarker levels using enzyme-linked immunosorbent assay (ELISA) and compared the results using the Mann-Whitney U-test. RESULTS: Significant elevations in neurodegenerative markers, including tau protein (p < 0.0001), phosphorylated tau protein (p < 0.0001), and clusterin (p = 0.038), were observed in ALS patients compared to controls. Elevated levels of tau protein and phosphorylated tau protein were also noted in both bulbar and limb-onset ALS patients. However, no significant difference was observed for beta-amyloid1-42. ROC analysis identified tau protein (AUC = 0.767) and p-tau protein (AUC = 0.719) as statistically significant predictors for ALS. CONCLUSION: Our study demonstrates that neurodegenerative marker levels indicate an ongoing neurodegenerative process in ALS. Nonetheless, the progression of ALS cannot be predicted solely based on these markers. The discovery of a specific biomarker could potentially complement existing diagnostic criteria for ALS.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24007639
003      
CZ-PrNML
005      
20240423160142.0
007      
ta
008      
240412s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s40001-023-01596-4 $2 doi
035    __
$a (PubMed)38184629
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Klíčová, Kateřina $u Department of Neurology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic. katerina.klicova@fnol.cz
245    10
$a Utilizing neurodegenerative markers for the diagnostic evaluation of amyotrophic lateral sclerosis / $c K. Klíčová, J. Mareš, K. Menšíková, M. Kaiserová, D. Friedecký, P. Kaňovský, M. Strnad, R. Matěj
520    9_
$a BACKGROUND: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterized by progressive deterioration of upper and lower motor neurons. A definitive diagnostic test or biomarker for ALS is currently unavailable, leading to a diagnostic delay following the onset of initial symptoms. Our study focused on cerebrospinal fluid (CSF) concentrations of clusterin, tau protein, phosphorylated tau protein, and beta-amyloid1-42 in ALS patients and a control group. METHODS: Our study involved 54 ALS patients and 58 control subjects. Among the ALS patients, 14 presented with bulbar-onset ALS, and 40 with limb-onset ALS. We quantified biomarker levels using enzyme-linked immunosorbent assay (ELISA) and compared the results using the Mann-Whitney U-test. RESULTS: Significant elevations in neurodegenerative markers, including tau protein (p < 0.0001), phosphorylated tau protein (p < 0.0001), and clusterin (p = 0.038), were observed in ALS patients compared to controls. Elevated levels of tau protein and phosphorylated tau protein were also noted in both bulbar and limb-onset ALS patients. However, no significant difference was observed for beta-amyloid1-42. ROC analysis identified tau protein (AUC = 0.767) and p-tau protein (AUC = 0.719) as statistically significant predictors for ALS. CONCLUSION: Our study demonstrates that neurodegenerative marker levels indicate an ongoing neurodegenerative process in ALS. Nonetheless, the progression of ALS cannot be predicted solely based on these markers. The discovery of a specific biomarker could potentially complement existing diagnostic criteria for ALS.
650    _2
$a lidé $7 D006801
650    12
$a amyotrofická laterální skleróza $x diagnóza $7 D000690
650    _2
$a klusterin $7 D051152
650    _2
$a opožděná diagnóza $7 D057210
650    _2
$a proteiny tau $7 D016875
650    _2
$a biologické markery $7 D015415
655    _2
$a časopisecké články $7 D016428
700    1_
$a Mareš, Jan $u Department of Neurology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic
700    1_
$a Menšíková, Kateřina $u Department of Neurology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic
700    1_
$a Kaiserová, Michaela $u Department of Neurology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic
700    1_
$a Friedecký, David $u Laboratory of Inherited Metabolic Disorders, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic Olomouc, Czech Republic
700    1_
$a Kaňovský, Petr $u Department of Neurology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic
700    1_
$a Strnad, Miroslav $u Department of Neurology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic $u Laboratory of Growth Regulators, Faculty of Science and Institute of Experimental Botany of the Czech Academy of Sciences, Palacky University Olomouc, Olomouc, Czech Republic
700    1_
$a Matěj, Radoslav $u Department of Pathology and Molecular Medicine, Third Faculty of Medicine, Charles University and Thomayer University Hospital, Prague, Czech Republic
773    0_
$w MED00181709 $t European journal of medical research $x 2047-783X $g Roč. 29, č. 1 (2024), s. 31
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38184629 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423160138 $b ABA008
999    __
$a ok $b bmc $g 2081558 $s 1217406
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 29 $c 1 $d 31 $e 20240106 $i 2047-783X $m European journal of medical research $n Eur J Med Res $x MED00181709
GRA    __
$a CZ.02.1.01 / 0.0 / 0.0 / 16_019 / 0000868 $p European Regional Development Fund - ENOCH project
GRA    __
$a NV19-04-00090 $p Grant Agency of the Ministry of Health
LZP    __
$a Pubmed-20240412

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...